{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:33:00Z","timestamp":1793071980353,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T00:00:00Z","timestamp":1365033600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40264-013-0032-z","type":"journal-article","created":{"date-parts":[[2013,4,3]],"date-time":"2013-04-03T05:35:55Z","timestamp":1364967355000},"page":"467-479","source":"Crossref","is-referenced-by-count":64,"title":["Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database"],"prefix":"10.1007","volume":"36","author":[{"given":"Elisabetta","family":"Poluzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariola","family":"Koci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah R.","family":"Behr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Sturkenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Ponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,4]]},"reference":[{"key":"32_CR1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1124\/pr.110.003723","volume":"62","author":"P Kannankeril","year":"2010","unstructured":"Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev. 2010;62:760\u201381.","journal-title":"Pharmacol Rev"},{"key":"32_CR2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/eurheartj\/ehs351","volume":"34","author":"ER Behr","year":"2013","unstructured":"Behr ER, Roden D. Drug-induced arrhythmia: pharmacogenomic prescribing? Eur Heart J. 2013;34:89\u201395.","journal-title":"Eur Heart J"},{"key":"32_CR3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200225040-00004","volume":"25","author":"F Ponti De","year":"2002","unstructured":"De Ponti F, Poluzzi E, Cavalli A, et al. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf. 2002;25:263\u201386.","journal-title":"Drug Saf"},{"key":"32_CR4","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","volume":"121","author":"BJ Drew","year":"2010","unstructured":"Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121:1047\u201360.","journal-title":"Circulation"},{"key":"32_CR5","doi-asserted-by":"crossref","first-page":"iv23","DOI":"10.1093\/europace\/eum168","volume":"9 Suppl 4","author":"B Darpo","year":"2007","unstructured":"Darpo B. Detection and reporting of drug-induced proarrhythmias: room for improvement. Europace. 2007;9 Suppl 4:iv23\u201336.","journal-title":"Europace"},{"key":"32_CR6","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2165\/00003495-200464100-00005","volume":"64","author":"RC Owens Jr","year":"2004","unstructured":"Owens RC Jr. QT prolongation with antimicrobial agents: understanding the significance. Drugs. 2004;64:1091\u2013124.","journal-title":"Drugs"},{"key":"32_CR7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1517\/17425250903055070","volume":"5","author":"E Raschi","year":"2009","unstructured":"Raschi E, Ceccarini L, De Ponti F, et al. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation. Expert Opin Drug Metab Toxicol. 2009;5:1005\u201321.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"32_CR8","unstructured":"The ARITMO project [online]. http:\/\/www.aritmo-project.org (Accessed May 7 2012)."},{"key":"32_CR9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/00002018-200629020-00008","volume":"29","author":"A Clarke","year":"2006","unstructured":"Clarke A, Deeks JJ, Shakir SA. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets. Drug Saf. 2006;29:175\u201381.","journal-title":"Drug Saf"},{"key":"32_CR10","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archpsyc.58.12.1161","volume":"58","author":"WA Ray","year":"2001","unstructured":"Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001;58:1161\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"32_CR11","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/bmj.325.7372.1070","volume":"325","author":"S Hennessy","year":"2002","unstructured":"Hennessy S, Bilker WB, Knauss JS, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ. 2002;325:1070.","journal-title":"BMJ"},{"key":"32_CR12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archinte.164.12.1293","volume":"164","author":"SM Straus","year":"2004","unstructured":"Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med. 2004;164:1293\u20137.","journal-title":"Arch Intern Med"},{"key":"32_CR13","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","volume":"294","author":"LS Schneider","year":"2005","unstructured":"Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934\u201343.","journal-title":"JAMA"},{"key":"32_CR14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2125.2009.03496.x","volume":"68","author":"K Jolly","year":"2009","unstructured":"Jolly K, Gammage MD, Cheng KK, et al. Sudden death in patients receiving drugs tending to prolong the QT interval. Br J Clin Pharmacol. 2009;68:743\u201351.","journal-title":"Br J Clin Pharmacol"},{"key":"32_CR15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","volume":"360","author":"WA Ray","year":"2009","unstructured":"Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225\u201335.","journal-title":"N Engl J Med"},{"key":"32_CR16","doi-asserted-by":"crossref","first-page":"936","DOI":"10.4088\/JCP.10m06244gry","volume":"72","author":"P Manu","year":"2011","unstructured":"Manu P, Kane JM, Correll CU. Sudden deaths in psychiatric patients. J Clin Psychiatry. 2011;72:936\u201341.","journal-title":"J Clin Psychiatry"},{"key":"32_CR17","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1542\/peds.2007-2008","volume":"121","author":"F Rani","year":"2008","unstructured":"Rani F, Murray ML, Byrne PJ, et al. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics. 2008;121:1002\u20139.","journal-title":"Pediatrics"},{"key":"32_CR18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2009.01425.x","volume":"121","author":"H Verdoux","year":"2010","unstructured":"Verdoux H, Tournier M, Begaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand. 2010;121:4\u201310.","journal-title":"Acta Psychiatr Scand"},{"key":"32_CR19","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00127-009-0123-4","volume":"45","author":"LC Wittkampf","year":"2010","unstructured":"Wittkampf LC, Smeets HM, Knol MJ, et al. Differences in psychotropic drug prescriptions among ethnic groups in the Netherlands. Soc Psychiatry Psychiatr Epidemiol. 2010;45:819\u201326.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"32_CR20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pds.2082","volume":"20","author":"GC Alexander","year":"2011","unstructured":"Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995\u20132008. Pharmacoepidemiol Drug Saf. 2011;20:177\u201384.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"32_CR21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/pds.1746","volume":"18","author":"E Poluzzi","year":"2009","unstructured":"Poluzzi E, Raschi E, Moretti U, et al. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. 2009;18:512\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"32_CR22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/11531850-000000000-00000","volume":"33","author":"E Poluzzi","year":"2010","unstructured":"Poluzzi E, Raschi E, Motola D, et al. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf. 2010;33:303\u201314.","journal-title":"Drug Saf"},{"key":"32_CR23","unstructured":"The FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files [online]. http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm082193.htm (Accessed May 7 2012)."},{"key":"32_CR24","unstructured":"MedWatch: The FDA Safety Information and Adverse Event Reporting Program [online]. http:\/\/www.fda.gov\/Safety\/MedWatch\/default.htm (Accessed May 7 2012)."},{"key":"32_CR25","first-page":"267","volume-title":"Data mining applications in engineering and medicine","author":"E Poluzzi","year":"2012","unstructured":"Poluzzi E, Raschi E, Piccinni C, et al. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). In: Karahoca A, editor. Data mining applications in engineering and medicine. Croatia: InTech; 2012. p. 267\u2013301."},{"key":"32_CR26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1476-5381.2009.00191.x","volume":"159","author":"RR Shah","year":"2010","unstructured":"Shah RR. Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives. Br J Pharmacol. 2010;159:58\u201369.","journal-title":"Br J Pharmacol"},{"key":"32_CR27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1365-2125.2011.04065.x","volume":"72","author":"E Raschi","year":"2011","unstructured":"Raschi E, Poluzzi E, Koci A, et al. QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus. Br J Clin Pharmacol. 2011;72:839\u201341.","journal-title":"Br J Clin Pharmacol"},{"key":"32_CR28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP Puijenbroek van","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"32_CR29","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1540-8159.1998.tb00148.x","volume":"21","author":"DM Roden","year":"1998","unstructured":"Roden DM. Taking the \u201cidio\u201d out of \u201cidiosyncratic\u201d: predicting torsades de pointes. Pacing Clin Electrophysiol. 1998;21:1029\u201334.","journal-title":"Pacing Clin Electrophysiol"},{"key":"32_CR30","unstructured":"The ArizonaCERT. Center for Education and Research on Therapeutics [online]. http:\/\/www.azcert.org\/ (Accessed May 7 2012)."},{"key":"32_CR31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/pds.1323","volume":"16","author":"WP Stephenson","year":"2007","unstructured":"Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf. 2007;16:359\u201365.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"32_CR32","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A, et al. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30:891\u20138.","journal-title":"Drug Saf"},{"key":"32_CR33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"32_CR34","doi-asserted-by":"crossref","unstructured":"Raschi E, Piccinni C, Poluzzi E, et al. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol (Epub Oct 19 2011).","DOI":"10.1007\/s00592-011-0340-7"},{"key":"32_CR35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/11587800-000000000-00000","volume":"25","author":"J Nielsen","year":"2011","unstructured":"Nielsen J, Graff C, Kanters JK, et al. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs. 2011;25:473\u201390.","journal-title":"CNS Drugs"},{"key":"32_CR36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31\u201341.","journal-title":"Lancet"},{"key":"32_CR37","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s11096-011-9541-y","volume":"33","author":"C Meyer-Massetti","year":"2011","unstructured":"Meyer-Massetti C, Vaerini S, Ratz Bravo AE, et al. Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case. Int J Clin Pharm. 2011;33:806\u201314.","journal-title":"Int J Clin Pharm"},{"key":"32_CR38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0014-2999(02)02074-5","volume":"450","author":"S Kongsamut","year":"2002","unstructured":"Kongsamut S, Kang J, Chen XL, et al. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol. 2002;450:37\u201341.","journal-title":"Eur J Pharmacol"},{"key":"32_CR39","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s11095-006-0070-7","volume":"23","author":"WJ Crumb Jr","year":"2006","unstructured":"Crumb WJ Jr, Ekins S, Sarazan RD, et al. Effects of antipsychotic drugs on I (to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res. 2006;23:1133\u201343.","journal-title":"Pharm Res"},{"key":"32_CR40","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejphar.2005.12.079","volume":"532","author":"W Crumb","year":"2006","unstructured":"Crumb W, Llorca PM, Lancon C, et al. Effects of cyamemazine on hERG, INa, ICa, Ito, Isus and IK1 channel currents, and on the QTc interval in guinea pigs. Eur J Pharmacol. 2006;532:270\u20138.","journal-title":"Eur J Pharmacol"},{"key":"32_CR41","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1211\/jpp.60.11.0012","volume":"60","author":"W Crumb","year":"2008","unstructured":"Crumb W, Benyamina A, Arbus C, et al. Cyamemazine metabolites: effects on human cardiac ion channels in-vitro and on the QTc interval in guinea pigs. J Pharm Pharmacol. 2008;60:1507\u201313.","journal-title":"J Pharm Pharmacol"},{"key":"32_CR42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.taap.2004.03.016","volume":"199","author":"K Titier","year":"2004","unstructured":"Titier K, Canal M, Deridet E, et al. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol Appl Pharmacol. 2004;199:52\u201360.","journal-title":"Toxicol Appl Pharmacol"},{"key":"32_CR43","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/JCP.0b013e3181e5c14c","volume":"30","author":"GK Isbister","year":"2010","unstructured":"Isbister GK, Balit CR, Macleod D, et al. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes. J Clin Psychopharmacol. 2010;30:391\u20135.","journal-title":"J Clin Psychopharmacol"},{"key":"32_CR44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/11208320-000000000-00000","volume":"72","author":"S Dhillon","year":"2012","unstructured":"Dhillon S. Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder. Drugs. 2012;72:133\u201362.","journal-title":"Drugs"},{"key":"32_CR45","volume-title":"The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust Prescribing Guidelines","year":"2010","unstructured":"Taylor D, Paton C, Kapur S, editors. The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust Prescribing Guidelines. 10th ed. London: Informa Healthcare; 2010.","edition":"10"},{"key":"32_CR46","doi-asserted-by":"crossref","unstructured":"Belgamwar RB, El-Sayeh HG. Aripiprazole versus placebo for schizophrenia. Cochrane Database Syst Rev. 2011;CD006622.","DOI":"10.1002\/14651858.CD006622.pub2"},{"key":"32_CR47","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/0269881110376685","volume":"25","author":"AK Chung","year":"2011","unstructured":"Chung AK, Chua SE. Effects on prolongation of Bazett\u2019s corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J Psychopharmacol. 2011;25:646\u201366.","journal-title":"J Psychopharmacol"},{"key":"32_CR48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/YIC.0b013e3283400d58","volume":"26","author":"DW Hough","year":"2011","unstructured":"Hough DW, Natarajan J, Vandebosch A, et al. Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2011;26:25\u201334.","journal-title":"Int Clin Psychopharmacol"},{"key":"32_CR49","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/FJC.0b013e318217d941","volume":"57","author":"P Vigneault","year":"2011","unstructured":"Vigneault P, Kaddar N, Bourgault S, et al. Prolongation of cardiac ventricular repolarization under paliperidone: how and how much? J Cardiovasc Pharmacol. 2011;57:690\u20135.","journal-title":"J Cardiovasc Pharmacol"},{"key":"32_CR50","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/hup.1258","volume":"27","author":"Y Suzuki","year":"2012","unstructured":"Suzuki Y, Fukui N, Watanabe J, et al. QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone. Hum Psychopharmacol. 2012;27:39\u201342.","journal-title":"Hum Psychopharmacol"},{"key":"32_CR51","doi-asserted-by":"crossref","first-page":"125ra31","DOI":"10.1126\/scitranslmed.3003377","volume":"4","author":"NP Tatonetti","year":"2012","unstructured":"Tatonetti NP, Ye PP, Daneshjou R, et al. Data-driven prediction of drug effects and interactions. Sci Transl Med. 2012;4:125ra31.","journal-title":"Sci Transl Med"},{"key":"32_CR52","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s002280100290","volume":"57","author":"F Ponti De","year":"2001","unstructured":"De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol. 2001;57:185\u2013209.","journal-title":"Eur J Clin Pharmacol"},{"key":"32_CR53","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/pds.2276","volume":"21","author":"J Papay","year":"2012","unstructured":"Papay J, Yuen N, Powell G, et al. Spontaneous adverse event reports of Stevens-Johnson syndrome\/toxic epidermal necrolysis: detecting associations with medications. Pharmacoepidemiol Drug Saf. 2012;21:289\u201396.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-013-0032-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-013-0032-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-013-0032-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T14:08:08Z","timestamp":1562854088000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-013-0032-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,4]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["32"],"URL":"https:\/\/doi.org\/10.1007\/s40264-013-0032-z","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,4]]}}}